Lord, Abbett & Co
REGN icon

Lord, Abbett & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Lord, Abbett & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-64,081
Closed -$67.4M – 573
2024
Q3 		$67.4M Sell
64,081
-22,151
-26% -$24.7M 0.21% 139
2024
Q2 		$90.6M Buy
86,232
+39,950
+86% +$38.7M 0.3% 93
2024
Q1 		$44.5M Buy
+46,282
New +$44M 0.14% 197
2020
Q3 		– Sell
-78,377
Closed -$48.9M – 674
2020
Q2 		$48.9M Buy
78,377
+32,960
+73% +$18.7M 0.17% 188
2020
Q1 		$22.2M Buy
+45,417
New +$18.7M 0.1% 309
2019
Q2 		– Sell
-36,117
Closed -$14.8M – 818
2019
Q1 		$14.8M Buy
+36,117
New +$14.9M 0.05% 478
2017
Q4 		– Sell
-44,268
Closed -$19.8M – 899
2017
Q3 		$19.8M Sell
44,268
-61,468
-58% -$29.2M 0.06% 477
2017
Q2 		$51.9M Buy
+105,736
New +$46.3M 0.15% 205
2016
Q4 		– Sell
-14,497
Closed -$5.83M – 943
2016
Q3 		$5.83M Sell
14,497
-13,212
-48% -$5.3M 0.02% 703
2016
Q2 		$9.68M Buy
27,709
+13,360
+93% +$5.15M 0.03% 590
2016
Q1 		$5.17M Sell
14,349
-54,981
-79% -$22.7M 0.02% 695
2015
Q4 		$37.6M Sell
69,330
-5,168
-7% -$2.8M 0.11% 279
2015
Q3 		$34.7M Sell
74,498
-15,430
-17% -$8.29M 0.1% 297
2015
Q2 		$45.9M Sell
89,928
-2,140
-2% -$1.04M 0.12% 274
2015
Q1 		$41.6M Buy
92,068
+20,617
+29% +$8.74M 0.11% 300
2014
Q4 		$29.3M Buy
71,451
+27,068
+61% +$10.6M 0.07% 376
2014
Q3 		$16M Buy
+44,383
New +$14.9M 0.04% 532
2013
Q4 		– Sell
-10,965
Closed -$3.43M – 1083
2013
Q3 		$3.43M Buy
+10,965
New +$2.88M 0.01% 885

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Lord, Abbett & Co's REGN Position: Q4 2024 in Review

Lord, Abbett & Co sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 64,081 shares — an estimated $67.4M sold.

Lord, Abbett & Co first reported a position in REGN in Q3 2013 and held it in 18 quarters. The position peaked at $90.6M in Q2 2024. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Lord, Abbett & Co reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Lord, Abbett & Co sold 64,081 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $67.4M.
  • Lord, Abbett & Co first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 18 quarters.
  • Lord, Abbett & Co's Regeneron Pharmaceuticals position peaked at $90.6M in Q2 2024.
  • 1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Lord, Abbett & Co's 13F filing for Q4 2024, filed 14 Feb 2025.